• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

When Can Intermediate Outcomes Be Used as Surrogate Outcomes?

作者信息

DeMets David L, Psaty Bruce M, Fleming Thomas R

机构信息

Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison.

Department of Medicine and Epidemiology, University of Washington, Seattle.

出版信息

JAMA. 2020 Mar 24;323(12):1184-1185. doi: 10.1001/jama.2020.1176.

DOI:10.1001/jama.2020.1176
PMID:32105291
Abstract
摘要

相似文献

1
When Can Intermediate Outcomes Be Used as Surrogate Outcomes?何时可将中间结果用作替代结果？
JAMA. 2020 Mar 24;323(12):1184-1185. doi: 10.1001/jama.2020.1176.
2
Treatment effects on patient-important outcomes can be small, even with large effects on surrogate markers.治疗效果对患者重要结局的影响可能很小，即使对替代指标有很大的影响。
J Clin Epidemiol. 2012 Sep;65(9):940-5. doi: 10.1016/j.jclinepi.2012.02.012. Epub 2012 May 18.
3
Assessing the value of a censored surrogate outcome.评估有删失的替代结局的价值。
Lifetime Data Anal. 2020 Apr;26(2):245-265. doi: 10.1007/s10985-019-09473-1. Epub 2019 Apr 12.
4
Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study.比较随机对照试验中替代和最终与患者相关结局的治疗效果大小：Meta 流行病学研究。
BMJ. 2013 Jan 29;346:f457. doi: 10.1136/bmj.f457.
5
Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation.使用患者管理作为诊断性检测评估中患者健康结局的替代指标。
BMC Med Res Methodol. 2012 Feb 14;12:12. doi: 10.1186/1471-2288-12-12.
6
Association of Surrogate Decision-making Interventions for Critically Ill Adults With Patient, Family, and Resource Use Outcomes: A Systematic Review and Meta-analysis.危重症成人代理决策干预与患者、家庭和资源使用结局的关联：系统评价和荟萃分析。
JAMA Netw Open. 2019 Jul 3;2(7):e197229. doi: 10.1001/jamanetworkopen.2019.7229.
7
How do validated measures of functional outcome compare with commonly used outcomes in administrative database research for lumbar spinal surgery?验证后的功能结果测量方法与腰椎脊柱手术的管理数据库研究中常用的结果相比如何？
Eur Spine J. 2010 Aug;19(8):1369-77. doi: 10.1007/s00586-009-1187-2. Epub 2009 Oct 9.
8
Surrogacy marker paradox measures in meta-analytic settings.荟萃分析环境中的替代标志物悖论测量
Biostatistics. 2015 Apr;16(2):400-12. doi: 10.1093/biostatistics/kxu043. Epub 2014 Sep 17.
9
Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence.在慢性髓性白血病一线治疗中，完全细胞遗传学缓解和主要分子学缓解作为总生存的替代终点：基于替代终点证据的技术评估案例研究。
Value Health. 2013 Sep-Oct;16(6):1081-90. doi: 10.1016/j.jval.2013.07.004.
10
Increasing the power of surrogate endpoint biomarkers: the aggregation of predictive factors.增强替代终点生物标志物的效能：预测因素的整合
J Cell Biochem Suppl. 1994;19:278-82.

引用本文的文献

1
Surrogate Outcomes Used as Proxies in Rare Long-Term Conditions: Evidence Assessment Group Perspective.在罕见长期病症中用作替代指标的替代结局：证据评估小组观点
Pharmacoeconomics. 2025 Aug 9. doi: 10.1007/s40273-025-01525-9.
2
Monitoring overall survival in pivotal trials in indolent cancers.监测惰性癌症关键试验中的总生存期。
Stat Biopharm Res. 2025;17(2):161-172. doi: 10.1080/19466315.2024.2365648. Epub 2024 Sep 3.
3
A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events.
关于妥善实施《国际人用药品注册技术协调会E9（R1）增编：处理并发事件的策略》的观点
Stat Med. 2025 May;44(10-12):e70104. doi: 10.1002/sim.70104.
4
Design considerations and challenges in the CHinA National CancEr Screening (CHANCES) trial and Tomosynthesis Mammographic Imaging Screening Trial (TMIST).中国国家癌症筛查（CHANCES）试验和乳腺断层合成钼靶成像筛查试验（TMIST）中的设计考量与挑战。
J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):42-48. doi: 10.1093/jncimonographs/lgae049.
5
Use of surrogate endpoints in health technology assessment: a review of selected NICE technology appraisals in oncology.替代终点在卫生技术评估中的应用：对英国国家卫生与临床优化研究所肿瘤学领域部分技术评估的综述
Int J Technol Assess Health Care. 2025 Feb 19;41(1):e11. doi: 10.1017/S0266462325000017.
6
Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review.既往接受过治疗的晚期实体癌二线或后续免疫检查点抑制剂的最佳早期终点：一项系统评价
BMC Cancer. 2025 Feb 18;25(1):293. doi: 10.1186/s12885-025-13712-0.
7
Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis.立体定向体部放疗与仑伐替尼治疗合并门静脉癌栓的肝细胞癌：倾向评分匹配分析。
Radiat Oncol. 2024 Oct 11;19(1):143. doi: 10.1186/s13014-024-02527-1.
8
Insights into the use of biomarkers in clinical trials in Alzheimer's disease.浅析生物标志物在阿尔茨海默病临床试验中的应用。
EBioMedicine. 2024 Oct;108:105322. doi: 10.1016/j.ebiom.2024.105322. Epub 2024 Oct 3.
9
Is Economic Evaluation and Care Commissioning Focused on Achieving the Same Outcomes? Resource-Allocation Considerations and Challenges Using England as a Case Study.经济评估和委托重点关注相同的结果吗？以英格兰为例的资源配置考虑因素和挑战。
Appl Health Econ Health Policy. 2024 Jul;22(4):435-445. doi: 10.1007/s40258-024-00875-3. Epub 2024 Mar 11.
10
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.特发性肺纤维化（IPF）临床试验的有意义终点：强调“感觉、功能、生存”。在一次研讨会上的合作讨论报告，患者代表、研究者、美国国立卫生研究院、一个患者权益倡导组织和一个监管机构直接参与了此次研讨会。
Am J Respir Crit Care Med. 2024 Mar 15;209(6):647-669. doi: 10.1164/rccm.202312-2213SO.